Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bicetre Hospital | OTHER |
| Centre Hospitalier Intercommunal Creteil | OTHER |
| University Hospital Southampton NHS Foundation Trust | OTHER |
| Universitaire Ziekenhuizen KU Leuven |
Not provided
Not provided
Not provided
Not provided
The Ear-Nose-Throat (ENT) Prospective International Cohort of patients with Primary Ciliary Dyskinesia (EPIC-PCD) is a prospective observational clinical cohort study, set up as a multinational multi-centre study. It is embedded into routine patient care of participating reference centres for PCD and patients keep being managed according to local procedures and guidelines.
The EPICD-PCD is hosted at the Institute of Social and Preventive Medicine (ISPM) at the University of Bern, Switzerland. Research is performed in close collaboration with all data contributors. This study aims to characterise ENT disease in PCD patients and its association with lower respiratory disease, and to identify determinants of its prognosis.
The investigators aim to:
Study design:
The EPIC-PCD is a prospective observational clinical cohort study, set up as a multinational multi-centre study. It is embedded into routine patient care of participating reference centres for PCD and patients will keep being managed according to local procedures and guidelines.
Patients with PCD are followed regularly at each centre, at 3-month to 6-month intervals. Each patient undergoes a detailed ENT sinonasal and otologic examination by ENT specialists, at minimum once a year, during a programmed follow-up visit. Additional ENT examinations are performed if indicated during in-between follow-up visits. Patients will not be subjected to additional invasive measurements solely for the purposes of the study.
What information is collected:
The study collect clinical data from patients assessment at regular consultations at the outpatient clinics.
For the collection of clinical data, participating centres will use FOLLOW-PCD, a disease-specific form for standardised prospective data collection during routine clinical follow-up of PCD patients.
Study database:
The EPIC-PCD database is web-based, using the Research Electronic Data Capture (REDCap) platform developed at Vanderbilt University. REDCap is widely used in academic research and allows data entry and extraction in various formats.
How to participate:
Centres that wish to participate to the project and contribute data can contact the EPIC-PCD managing centre to sign a data delivery agreement. They then will receive a password to access the online software REDCap and they will be able to enter their data directly. They can also upload follow-up data or add additional patients at a later time point.
Funding:
The setting up of the EPIC-PCD (salaries, consumables and equipment) was funded by the Swiss National Science Foundation. Data collection and management at each site was funded according to local arrangements. Most participating researchers and data contributors participate in the European Respiratory Society Clinical Research collaboration "Better Evidence to Advance Therapeutic options for PCD" (BEAT-PCD) (https://beat-pcd.squarespace.com/). Infrastructure is provided for free by the University of Bern, where the data are pooled and stored.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Sinonasal symptoms and signs | Prevalence of reported clinical symptoms at different age groups, including rhinitis, sinusitis, snoring | at baseline |
| Course of sinonasal symptoms and signs (year 1) | Change from baseline prevalence of reported clinical symptoms at different age groups, including rhinitis, sinusitis, snoring, at 12 months | at 12 months from recruitment |
| Course of sinonasal symptoms and signs (year 2) | Change from baseline prevalence of reported clinical symptoms at different age groups, including rhinitis, sinusitis, snoring, at 24 months | at 24 months from recruitment |
| Otological symptoms and signs | Prevalence of reported clinical symptoms at different age groups, including ear pain, hearing problems, ear discharge | at baseline |
| Course of otological symptoms and signs (year 1) | Change from baseline prevalence of reported clinical symptoms at different age groups, including ear pain, hearing problems, ear discharge, at 12 months | at 12 months from recruitment |
| Course of otological symptoms and signs (year 2) | Change from baseline prevalence of reported clinical symptoms at different age groups, including ear pain, hearing problems, ear discharge, at 24 months | at 24 months from recruitment |
| Nasal endoscopy (description of nasal mucosa) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
None
Not provided
Not provided
Not provided
Not provided
Patients of all ages diagnosed with PCD, followed in a collaborating PCD centre
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Myrofora Goutaki, MD-PhD | Contact | 0041 316315973 | myrofora.goutaki@unibe.ch |
| Name | Affiliation | Role |
|---|---|---|
| Myrofora Goutaki, MD-PhD | University of Bern | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Bern | Recruiting | Bern | Switzerland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34635525 | Derived | Goutaki M, Lam YT, Alexandru M, Anagiotos A, Armengot M, Bequignon E, Boon M, Burgess A, Coste A, Emiralioglu N, Erdem E, Haarman EG, Harris A, Hool SL, Karadag B, Kim S, Latzin P, Lorent N, Ozcelik U, Reula A, Roehmel J, van Gogh C, Yiallouros P, Zappe SM; EPIC-PCD team; Papon JF. Study protocol: the ear-nose-throat (ENT) prospective international cohort of patients with primary ciliary dyskinesia (EPIC-PCD). BMJ Open. 2021 Oct 11;11(10):e051433. doi: 10.1136/bmjopen-2021-051433. |
Not provided
Not provided
Not all participating centres have ethical approval to share IPD to external researchers.
Researchers wanting to use the dataset can propose a research topic and draft a concept sheet describing the planned analyses and publication. All concept sheets have to be approved by all participating centres contributing data to the proposed analysis under question. After the participating centres agree to contribute their data and sign a publication agreement, the EPIC-PCD managing centre (University of Bern) will prepare a partial dataset for the proposed analysis and will work closely with the lead researchers offering methodological input and support. In case additional data is collected to complete the partial dataset for a specific project, this will be added to the EPIC-PCD dataset to enrich it after each project.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002925 | Ciliary Motility Disorders |
| D007619 | Kartagener Syndrome |
| ID | Term |
|---|---|
| D012140 | Respiratory Tract Diseases |
| D010038 | Otorhinolaryngologic Diseases |
| D000072661 | Ciliopathies |
| D000015 | Abnormalities, Multiple |
Not provided
Not provided
| OTHER |
| Amsterdam UMC, location VUmc | OTHER |
| University of Cyprus | OTHER |
| Hacettepe University | OTHER |
| Marmara University | OTHER |
| Hospital Universitario La Fe | OTHER |
| Insel Gruppe AG, University Hospital Bern | OTHER |
Not provided
Not provided
Not provided
Description of nasal mucosa as seen via nasal endoscopy examination |
| at baseline |
| Nasal endoscopy (changes of nasal mucosa at year 1) | Changes in nasal mucosa from baseline as seen via nasal endoscopy examination at 12 months | at 12 months from recruitment |
| Nasal endoscopy (changes of nasal mucosa at year 2) | Changes in nasal mucosa from baseline as seen via nasal endoscopy examination at 24 months | at 24 months from recruitment |
| Nasal endoscopy (nasal polyps) | Prevalence of nasal polyps at baseline | at baseline |
| Nasal endoscopy (nasal polyps at year 1) | Changes in prevalence of nasal polyps from baseline to 12 months | at 12 months from recruitment |
| Nasal endoscopy (nasal polyps at year 2) | Changes in prevalence of nasal polyps from baseline to 24 months | at 24 months from recruitment |
| Sinonasal examination (Lidholdt score) | Lidholdt score at baseline | at baseline |
| Sinonasal examination (Lidholdt score at year 1) | Changes in Lidholdt score from baseline to 12 months | at 12 months from recruitment |
| Sinonasal examination (Lidholdt score at year 2) | Changes in Lidholdt score from baseline to 24 months | at 24 months from recruitment |
| Ear examination (ear discharge) | Prevalence of ear discharge at baseline | at baseline |
| Ear examination (ear discharge at year 1) | Changes in prevalence of ear discharge from baseline to 12 months | at 12 months from recruitment |
| Ear examination (ear discharge at year 2) | Changes in prevalence of ear discharge from baseline to 24 months | at 24 months from recruitment |
| Otoscopy (description of the tympanic membrane) | Description of tympanic membrane as seen via otoscopy examination | at baseline |
| Otoscopy (description of the tympanic membrane at year 1) | Changes in the tympanic membrane from baseline to 12 months as seen via otoscopy examination | at 12 months from recruitment |
| Otoscopy (description of the tympanic membrane at year 2) | Changes in the tympanic membrane from baseline to 24 months as seen via otoscopy examination | at 24 months from recruitment |
| Tympanometry | Results of tympanometry (tympanogram type for both ears) at baseline | at baseline |
| Tympanometry (at year 1) | Changes in tympanogram (for both ears) from baseline to 12 months | at 12 months from recruitment |
| Tympanometry (at year 2) | Changes in tympanogram (for both ears) from baseline to 24 months | at 24 months from recruitment |
| Audiometry | Results of audiometry: type of audiometry and results based on WHO hearing loss grades (for both ears) | at baseline |
| Audiometry (at year 1) | Changes in audiometry results from baseline to 12 months | at 12 months from recruitment |
| Audiometry (at year 2) | Changes in audiometry results from baseline to 24 months | at 24 months from recruitment |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D030342 | Genetic Diseases, Inborn |
| D001987 | Bronchiectasis |
| D001982 | Bronchial Diseases |
| D015619 | Respiratory System Abnormalities |
| D003914 | Dextrocardia |
| D006330 | Heart Defects, Congenital |
| D018376 | Cardiovascular Abnormalities |
| D002318 | Cardiovascular Diseases |
| D006331 | Heart Diseases |
| D012857 | Situs Inversus |